![]() ![]() | ZAGARE, A., SAUTER, T., BARMPA, K., PIRES PACHECO, M. I., KRÜGER, R., SCHWAMBORN, J. C., & SARAIVA, C. (17 April 2025). MIRO1 mutation leads to metabolic maladaptation resulting in Parkinson's disease-associated dopaminergic neuron loss. NPJ Systems Biology and Applications, 11 (1), 37. doi:10.1038/s41540-025-00509-x ![]() |
![]() ![]() | BARMPA, K. (2023). ENHANCING THE COMPLEXITY OF 3D IN VITRO MODELS FOR PARKINSON'S DISEASE RESEARCH [Doctoral thesis, Unilu - University of Luxembourg]. ORBilu-University of Luxembourg. https://orbilu.uni.lu/handle/10993/57742 |
![]() ![]() | GARCIA SANTA CRUZ, B., Sölter, J., GOMEZ GIRO, G., SARAIVA, C., SABATÉ SOLER, S., Modamio Chamarro, J., BARMPA, K., SCHWAMBORN, J. C., HERTEL, F., JARAZO, J., & HUSCH, A. (2022). Generalising from conventional pipelines using deep learning in high‑throughput screening workfows. Scientific Reports. doi:10.1038/s41598-022-15623-7 ![]() |
![]() ![]() | ZAGARE, A., BARMPA, K., SMAJIC, S., SMITS, L., GRZYB, K., GRÜNEWALD, A., SKUPIN, A., NICKELS, S. L., & SCHWAMBORN, J. C. (2022). Midbrain organoids mimic early embryonic neurodevelopment and recapitulate LRRK2-p.Gly2019Ser-associated gene expression. American Journal of Human Genetics. doi:10.1016/j.ajhg.2021.12.009 ![]() |
![]() ![]() | SABATÉ SOLER, S., NICKELS, S. L., SARAIVA, C., Berger, E., Dubonyte, U., BARMPA, K., Lan, Y. J., Kouno, T., JARAZO, J., ROBERTSON, G., Sharif, J., Koseki, H., Thome, C., Shin, J., Cowley, S., & SCHWAMBORN, J. C. (2022). Microglia integration into human midbrain organoids leads to increased neuronal maturation and functionality. Glia. doi:10.1002/glia.24167 ![]() |
![]() ![]() | JARAZO, J., BARMPA, K., Modamio, J., SARAIVA, C., SABATÉ SOLER, S., ROSETY, I., Griesbeck, A., Skwirblies, F., Zaffaroni, G., SMITS, L., Su, J., Arias-Fuenzalida, Walter, J., GOMEZ GIRO, G., Monzel, A., Qing, X., VITALI, A., CRUCIANI, G., BOUSSAAD, I., ... SCHWAMBORN, J. C. (2021). Parkinson’s disease phenotypes in patient neuronal cultures and brain organoids improved by 2-Hydroxypropyl-b-Cyclodextrin treatment. Movement Disorders. doi:10.1002/mds.28810 ![]() |